Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p

Luo,Shunxiang; Shen,Ming; Chen,Hui; Li,Weiwei; Chen,Cong

doi:10.3892/mmr.2020.11473

Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p

Authors:
- Shunxiang Luo
- Ming Shen
- Hui Chen
- Weiwei Li
- Cong Chen
View Affiliations

Affiliations: Department of Oncology, The First People's Hospital of Tianmen, Tianmen, Hubei 431700, P.R. China
Published online on: September 1, 2020 https://doi.org/10.3892/mmr.2020.11473
Pages: 3822-3832
Copyright: © Luo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Non‑small cell lung cancer (NSCLC) is a leading subtype of lung cancer, with high mortality rates. Recently, long non‑coding RNAs (lncRNAs) have been associated with NSCLC. The present study aimed to examine the role of the TP73 antisense RNA 1 (TP73‑AS1) lncRNA in NSCLC. TP73‑AS1 and microRNA(miR)‑34a‑5p expression levels were measured using reverse transcription‑quantitative PCR (RT‑qPCR) and chromogenic in situ hybridization (CISH). Cell proliferation, apoptosis, migration and invasion was determined using Cell Counting Kit‑8 (CCK‑8), flow cytometry, Transwell and Matrigel assays, respectively. The median inhibitory concentration (IC50) value of cisplatin (cis‑diamminedichloroplatinum; DDP) was assessed using a CCK‑8 assay. The interaction between miR‑34a‑5p and TP73‑AS1 or tripartite motif‑containing 29 (TRIM29) was predicted using microRNA.org and Starbase, then verified using a dual‑luciferase reporter assay. The expression of TRIM29 was quantified at the mRNA and protein level using RT‑qPCR and western blot analysis, respectively. TP73‑AS1 was significantly upregulated, while miR‑34a‑5p was downregulated in NSCLC tissues and cells. Functionally, TP73‑AS1 knockdown inhibited proliferation, migration, invasion and DDP resistance, whilst inducing apoptosis in NSCLC cells. miR‑34a‑5p was identified as a target for TP73‑AS1, and its inhibition reversed the effects of TP73‑AS1 knockdown on NSCLC cells. In addition, TRIM29 was targeted by miR‑34a‑5p, and its overexpression reversed the effects of miR‑34a‑5p. Moreover, TP73‑AS1 acted as a molecular sponge for miR‑34a‑5p, increasing the expression of TRIM29. In conclusion, TP73‑AS1 contributed to proliferation, migration and DDP resistance but inhibited apoptosis of NSCLC cells by upregulating TRIM29 and sponging miR‑34a‑5p.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
2	Papaetis GS, Roussos C and Syrigos KN: Targeted therapies for non-small cell lung cancer. Curr Pharm Des. 13:2810–2831. 2007. View Article : Google Scholar : PubMed/NCBI
3	Fan WD, Zhang XQ, Guo HL, Zeng WW, Zhang N, Wan QQ, Xie WY, Cao J and Xu CH: Bioinformatics analysis reveals connection of squamous cell carcinoma and adenocarcinoma of the lung. Asian Pac J Cancer Prev. 13:1477–1482. 2012. View Article : Google Scholar : PubMed/NCBI
4	Younes RN, Pereira JR, Fares AL and Gross JL: Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras (1992). 57:686–691. 2011. View Article : Google Scholar : PubMed/NCBI
5	Gainor JF and Shaw AT: Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 18:865–875. 2013. View Article : Google Scholar : PubMed/NCBI
6	Spizzo R, Almeida MI, Colombatti A and Calin GA: Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
7	Dimartino D, Colantoni A, Ballarino M, Martone J, Mariani D, Danner J, Bruckmann A, Meister G, Morlando M and Bozzoni I: The long non-coding RNA lnc-31 interacts with Rock1 mRNA and mediates its YB-1-dependent translation. Cell Rep. 23:733–740. 2018. View Article : Google Scholar : PubMed/NCBI
8	Shi X, Liu Z, Liu Z, Feng X, Hua F, Hu X, Wang B, Lu K and Nie F: Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer. EBioMedicine. 37:177–187. 2018. View Article : Google Scholar : PubMed/NCBI
9	Lu Q, Shan S, Li Y, Zhu D, Jin W and Ren T: Long noncoding RNA SNHG1 promotes non-small cell lung cancer progression by up-regulating MTDH via sponging miR-145-5p. FASEB J. 32:3957–3967. 2018. View Article : Google Scholar : PubMed/NCBI
10	Tan J and Yang L: Long noncoding RNA VPS9D1-AS1 overexpression predicts a poor prognosis in non-small cell lung cancer. Biomed Pharmacother. 106:1600–1606. 2018. View Article : Google Scholar : PubMed/NCBI
11	Varon M, Levy T, Mazor G, Ben David H, Marciano R, Krelin Y, Prasad M, Elkabets M, Pauck D, Ahmadov U, et al: The long noncoding RNA TP73-AS1 promotes tumorigenicity of medulloblastoma cells. Int J Cancer. 145:3402–3413. 2019. View Article : Google Scholar : PubMed/NCBI
12	Liu G, Zhao X, Zhou J, Cheng X, Ye Z and Ji Z: lncRNA TP73-AS1 promotes cell proliferation and inhibits cell apoptosis in clear cell renal cell carcinoma through repressing KISS1 expression and inactivation of PI3K/Akt/mTOR signaling pathway. Cell Physiol Biochem. 48:371–384. 2018. View Article : Google Scholar : PubMed/NCBI
13	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
14	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
15	Shukla GC, Singh J and Barik S: MicroRNAs: Processing, maturation, target recognition and regulatory functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
16	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, function and role in cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
17	Gao J, Li N, Dong Y, Li S, Xu L, Li X, Li Y, Li Z, Ng SS, Sung JJ, et al: miR-34a-5p suppresses colorectal cancer metastasis and predicts recurrence in patients with stage II/III colorectal cancer. Oncogene. 34:4142–4152. 2015. View Article : Google Scholar : PubMed/NCBI
18	Zhong Z, Zhou F, Wang D, Wu M, Zhou W, Zou Y, Li J, Wu L and Yin X: Expression of KLF9 in pancreatic cancer and its effects on the invasion, migration, apoptosis, cell cycle distribution, and proliferation of pancreatic cancer cell lines. Oncol Rep. 40:3852–3860. 2018.PubMed/NCBI
19	Sun Z, Zhang B and Cui T: Long non-coding RNA XIST exerts oncogenic functions in pancreatic cancer via miR-34a-5p. Oncol Rep. 39:1591–1600. 2018.PubMed/NCBI
20	Kosaka Y, Inoue H, Ohmachi T, Yokoe T, Matsumoto T, Mimori K, Tanaka F, Watanabe M and Mori M: Tripartite motif-containing 29 (TRIM29) is a novel marker for lymph node metastasis in gastric cancer. Ann Surg Oncol. 14:2543–2549. 2007. View Article : Google Scholar : PubMed/NCBI
21	Masuda Y, Takahashi H, Sato S, Tomomori-Sato C, Saraf A, Washburn MP, Florens L, Conaway RC, Conaway JW and Hatakeyama S: TRIM29 regulates the assembly of DNA repair proteins into damaged chromatin. Nat Commun. 6:72992015. View Article : Google Scholar : PubMed/NCBI
22	Napolitano LM and Meroni G: TRIM family: Pleiotropy and diversification through homomultimer and heteromultimer formation. IUBMB Life. 64:64–71. 2012. View Article : Google Scholar : PubMed/NCBI
23	Ai L, Kim WJ, Alpay M, Tang M, Pardo CE, Hatakeyama S, May WS, Kladde MP, Heldermon CD, Siegel EM and Brown KD: TRIM29 suppresses TWIST1 and invasive breast cancer behavior. Cancer Res. 74:4875–4887. 2014. View Article : Google Scholar : PubMed/NCBI
24	Qiu F, Xiong JP, Deng J and Xiang XJ: TRIM29 functions as an oncogene in gastric cancer and is regulated by miR-185. Int J Clin Exp Pathol. 8:5053–5061. 2015.PubMed/NCBI
25	Xu J, Li Z, Su Q, Zhao J and Ma J: TRIM29 promotes progression of thyroid carcinoma via activating P13K/AKT signaling pathway. Oncol Rep. 37:1555–1564. 2017. View Article : Google Scholar : PubMed/NCBI
26	Tan ST, Liu SY and Wu B: TRIM29 overexpression promotes proliferation and survival of bladder cancer cells through NF-κB signaling. Cancer Res Treat. 48:1302–1312. 2016. View Article : Google Scholar : PubMed/NCBI
27	Edge SB and Compton CC: The American joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
29	Balata H, Fong KM, Hendriks LE, Lam S, Ostroff JS, Peled N, Wu N and Aggarwal C: Prevention and early detection for NSCLC: Advances in thoracic oncology 2018. J Thorac Oncol. 14:1513–1527. 2019. View Article : Google Scholar : PubMed/NCBI
30	Zhu D, Zhou J, Liu Y, Du L, Zheng Z and Qian X: lncRNA TP73-AS1 is upregulated in non-small cell lung cancer and predicts poor survival. Gene. 710:98–102. 2019. View Article : Google Scholar : PubMed/NCBI
31	Zhang L, Fang F and He X: Long noncoding RNA TP73-AS1 promotes non-small cell lung cancer progression by competitively sponging miR-449a/EZH2. Biomed Pharmacother. 104:705–711. 2018. View Article : Google Scholar : PubMed/NCBI
32	Mazor G, Levin L, Picard D, Ahmadov U, Carén H, Borkhardt A, Reifenberger G, Leprivier G, Remke M and Rotblat B: The lncRNA TP73-AS1 is linked to aggressiveness in glioblastoma and promotes temozolomide resistance in glioblastoma cancer stem cells. Cell Death Dis. 10:2462019. View Article : Google Scholar : PubMed/NCBI
33	Chen B, Shen Z, Wu D, Xie X, Xu X, Lv L, Dai H, Chen J and Gan X: Glutathione peroxidase 1 promotes NSCLC resistance to cisplatin via ROS-induced activation of PI3K/AKT pathway. Biomed Res Int. 2019:76405472019.PubMed/NCBI
34	Zhang Y, Zheng S, Zheng JS, Wong KH, Huang Z, Ngai SM, Zheng W, Wong YS and Chen T: Synergistic induction of apoptosis by methylseleninic acid and cisplatin, the role of ROS-ERK/AKT-p53 pathway. Mol Pharm. 11:1282–1293. 2014. View Article : Google Scholar : PubMed/NCBI
35	Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E and Kater AP: ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene. 30:701–713. 2011. View Article : Google Scholar : PubMed/NCBI
36	Jiao DM, Yan L, Wang LS, Hu HZ, Tang XL, Chen J, Wang J, Li Y and Chen QY: Exploration of inhibitory mechanisms of curcumin in lung cancer metastasis using a miRNA-transcription factor-target gene network. PLoS One. 12:e01724702017. View Article : Google Scholar : PubMed/NCBI
37	Jiang ZQ, Li MH, Qin YM, Jiang HY, Zhang X and Wu MH: Luteolin inhibits tumorigenesis and induces apoptosis of non-small cell lung cancer cells via regulation of MicroRNA-34a-5p. Int J Mol Sci. 19:4472018. View Article : Google Scholar
38	Wang X, Dong K, Gao P, Long M, Lin F, Weng Y, Ouyang Y, Ren J and Zhang H: MicroRNA-34a sensitizes lung cancer cell lines to DDP treatment independent of p53 status. Cancer Biother Radiopharm. 28:45–50. 2013. View Article : Google Scholar : PubMed/NCBI
39	Zhang Z, Kong Y, Yang W, Ma F, Zhang Y, Ji S, Ma EM, Liu H, Chen Y and Hua Y: Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncol Rep. 36:2391–2397. 2016. View Article : Google Scholar : PubMed/NCBI
40	Xu M, Hu J, Zhou B, Zhong Y, Lin N and Xu R: TRIM29 prevents hepatocellular carcinoma progression by inhibiting Wnt/β-catenin signaling pathway. Acta Biochim Biophys Sin (Shanghai). 51:68–77. 2019. View Article : Google Scholar : PubMed/NCBI
41	Song X, Fu C, Yang X, Sun D, Zhang X and Zhang J: Tripartite motif-containing 29 as a novel biomarker in non-small cell lung cancer. Oncol Lett. 10:2283–2288. 2015. View Article : Google Scholar : PubMed/NCBI
42	Zhan W, Han T, Zhang C, Xie C, Gan M, Deng K, Fu M and Wang JB: TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI
43	Liu C, Huang X, Hou S, Hu B and Li H: Silencing of tripartite motif (TRIM) 29 inhibits proliferation and invasion and increases chemosensitivity to cisplatin in human lung squamous cancer NCI-H520 cells. Thorac Cancer. 6:31–37. 2015. View Article : Google Scholar : PubMed/NCBI